Kymera Therapeutics, (id:6435 KYMR)
44.98 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 6:54:30 PM)
Exchange closed, opens in 1 day 14 hours
About Kymera Therapeutics,
Market Capitalization 3.24B
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Headquarters (address) |
200 Arsenal Yards Boulevard Watertown 02472 MA United States |
| Phone | 857 285 5300 |
| Website | https://www.kymeratx.com |
| Employees | 184 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | KYMR |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 18.89 - 53.27 |
| Market Capitalization | 3.24B |
| P/E trailing | -17.85 |
| P/E forward | -16.08 |
| Price/Sale | 36.98 |
| Price/Book | 3.63 |
| Beta | 2.22 |
| EPS | -2.34 |
| EPS United States (ID:6, base:3403) | 24.22 |